Adding Nivolumab to Standard Care Does Not Improve Survival in Glioblastoma
The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.
The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.
There was no improvement in progression-free or overall survival with marizomib.
Investigators performed immunohistochemistry on glioblastoma tumor samples in an effort to identify molecular subtypes associated with treatment sensitivities.
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
Use of dexamethasone was associated with shorter survival in those with glioblastoma treated with a PD-1/PD-L1 inhibitor.
A new approach combining inducible gene therapy and an anti–PD-1 shows promise in hard-to-treat brain tumors.
Nivolumab monotherapy fails to improve OS compared to bevacizumab in the treatment of recurrent glioblastoma.
A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival.
Researchers have engineered CAR-T cells to express a peptide from scorpion venom to help them home to glioma cells.
A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.